Related Experiment Video
Updated: May 15, 2026

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes
David van Duin1, Keith S Kaye, Elizabeth A Neuner
1Department of Infectious Diseases, Cleveland Clinic, Cleveland, OH, USA. vanduid@ccf.org
Abstract:
The emergence of carbapenem resistance in Enterobacteriaceae is an important threat to global health. Reported outcomes of infections with carbapenem-resistant Enterobacteriaceae (CRE) are poor. Very few options remain for the treatment of these virulent organisms. Antibiotics which are currently in use to treat CRE infections include aminoglycosides, polymyxins, tigecycline, fosfomycin, and temocillin. In addition, the role of combination therapy, including carbapenem containing regimens, remains to be defined. There are several important concerns regarding all of these treatment options such as limited efficacy, increasing reports of resistance, and specific toxicities. Data from retrospective studies favor combination therapy over single-agent therapy for the treatment of CRE bloodstream infections. In summary, new antibiotics are greatly needed, as is additional prospective research.
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Clinical Significance of Antibiotic Resistance
Mechanism of Antibiotic Resistance in MRSA
Treatment Resistent Cancers
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Endocarditis III: Medical Management